These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1238 related items for PubMed ID: 22244025

  • 1. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.
    Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI.
    J Clin Psychiatry; 2011 Dec; 72(12):1660-8. PubMed ID: 22244025
    [Abstract] [Full Text] [Related]

  • 2. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.
    Iovieno N, Tedeschini E, Bentley KH, Evins AE, Papakostas GI.
    J Clin Psychiatry; 2011 Aug; 72(8):1144-51. PubMed ID: 21536001
    [Abstract] [Full Text] [Related]

  • 3. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.
    Freeman MP, Mischoulon D, Tedeschini E, Goodness T, Cohen LS, Fava M, Papakostas GI.
    J Clin Psychiatry; 2010 Jun; 71(6):682-8. PubMed ID: 20573327
    [Abstract] [Full Text] [Related]

  • 4. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 5. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P.
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [Abstract] [Full Text] [Related]

  • 6. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Iovieno N, Papakostas GI.
    J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
    [Abstract] [Full Text] [Related]

  • 7. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.
    Tedeschini E, Fava M, Papakostas GI.
    J Clin Psychiatry; 2011 Jan; 72(1):98-113. PubMed ID: 21208576
    [Abstract] [Full Text] [Related]

  • 8. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.
    Iovieno N, Papakostas GI.
    J Clin Psychiatry; 2012 Oct; 73(10):1300-6. PubMed ID: 23140647
    [Abstract] [Full Text] [Related]

  • 9. Beneficial and harmful effects of antidepressants versus placebo, 'active placebo', or no intervention for adults with major depressive disorder: a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses.
    Juul S, Siddiqui F, Barbateskovic M, Jørgensen CK, Hengartner MP, Kirsch I, Gluud C, Jakobsen JC.
    Syst Rev; 2021 May 25; 10(1):154. PubMed ID: 34034811
    [Abstract] [Full Text] [Related]

  • 10. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
    Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR.
    Lancet; 2018 Apr 07; 391(10128):1357-1366. PubMed ID: 29477251
    [Abstract] [Full Text] [Related]

  • 11. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
    Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, Iwata N.
    Mol Psychiatry; 2023 Jan 07; 28(1):402-409. PubMed ID: 36253442
    [Abstract] [Full Text] [Related]

  • 12. Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
    Hayasaka Y, Purgato M, Magni LR, Ogawa Y, Takeshima N, Cipriani A, Barbui C, Leucht S, Furukawa TA.
    J Affect Disord; 2015 Jul 15; 180():179-84. PubMed ID: 25911132
    [Abstract] [Full Text] [Related]

  • 13. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
    Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C, Coghill D, Zhang Y, Hazell P, Leucht S, Cuijpers P, Pu J, Cohen D, Ravindran AV, Liu Y, Michael KD, Yang L, Liu L, Xie P.
    Lancet; 2016 Aug 27; 388(10047):881-90. PubMed ID: 27289172
    [Abstract] [Full Text] [Related]

  • 14. Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis.
    Pedrelli P, Iovieno N, Vitali M, Tedeschini E, Bentley KH, Papakostas GI.
    J Clin Psychopharmacol; 2011 Oct 27; 31(5):582-6. PubMed ID: 21869696
    [Abstract] [Full Text] [Related]

  • 15. [Comparative efficacy and acceptability of new-generation antidepressants. Synthesis meta-analysis Cipriani].
    Gaillard R.
    Encephale; 2009 Oct 27; 35(5):499-504. PubMed ID: 19853726
    [Abstract] [Full Text] [Related]

  • 16. Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials.
    Iovieno N, Tedeschini E, Ameral VE, Rigatelli M, Papakostas GI.
    Int Clin Psychopharmacol; 2011 Mar 27; 26(2):69-74. PubMed ID: 20962663
    [Abstract] [Full Text] [Related]

  • 17. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA, Chen YF, Yang Y, Yang P, Laughren TP.
    J Clin Psychiatry; 2011 Apr 27; 72(4):464-72. PubMed ID: 21527123
    [Abstract] [Full Text] [Related]

  • 18. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.
    Papakostas GI, Fava M.
    Eur Neuropsychopharmacol; 2009 Jan 27; 19(1):34-40. PubMed ID: 18823760
    [Abstract] [Full Text] [Related]

  • 19. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.
    Khoo AL, Zhou HJ, Teng M, Lin L, Zhao YJ, Soh LB, Mok YM, Lim BP, Gwee KP.
    CNS Drugs; 2015 Aug 27; 29(8):695-712. PubMed ID: 26293743
    [Abstract] [Full Text] [Related]

  • 20. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.
    Carpenter DJ, Fong R, Kraus JE, Davies JT, Moore C, Thase ME.
    J Clin Psychiatry; 2011 Nov 27; 72(11):1503-14. PubMed ID: 21367354
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.